Dupixent approved in the US as the first-ever biologic medicine …
WEB4 days ago · Paris and Tarrytown, NY, September 27, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is the first biologic medicine approved in the US to treat these ...
Sanofi and Regeneron Biologic Drug Dupixent Notches a New …
WEB1 day ago · Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
WEB1 day ago · LLY. Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD) — in ...
Dupixent® (dupilumab) Approved in the U.S. as the First-ever
WEB3 days ago · Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Following recent ...
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB3 days ago · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up to six ...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB4 days ago · Dupixent is now cleared for use as an add-on maintenance treatment for adults with a certain kind of chronic obstructive pulmonary disease, or COPD, that can’t be controlled with other medications. The decision makes Dupixent the first biologic medicine approved in the U.S. for COPD, a lung disease that makes it …
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
WEB3 days ago · REGN. With the latest nod from the US Food and Drug Administration (FDA), Regeneron Pharmaceuticals and Sanofi have expanded the US label of Dupixent (dupilumab) to treat chronic obstructive ...
Dupixent® late-breaking data from NOTUS confirmatory phase 3 …
WEBMay 20, 2024 · NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation.
Dupixent® (dupilumab) Significantly Reduced COPD …
WEBNov 27, 2023 · NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL), confirming results from the landmark BOREAS pivotal trial.
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive ...
WEB3 days ago · Sanofi claimed that Dupixent will be nation's first biologic medicine approved for these conditions. COPD is a respiratory disease that damages the lungs and causes progressive lung function decline.